視神經脊髓炎頻譜障礙市場規模、佔有率和成長分析：按治療方法、AQP4狀態、通路、最終用戶和地區分類－2026-2033年產業預測

2024 年全球視神經脊髓炎頻譜疾病 (NMOSD) 市值為 15.2 億美元，預計到 2025 年將成長至 17.1 億美元，到 2033 年將成長至 45.2 億美元，在預測期（2026-2033 年）內複合成長率為 12.82%。

視神經脊髓炎頻譜障礙 (NMOSD) 市場受到診斷技術進步的顯著影響，尤其是水通道蛋白 4 IgG 檢測技術的開發。該檢測技術提高了疾病識別的準確性，並增加了報告的盛行率。這項進展推動了對標靶治療的需求，領先的製藥公司正從傳統的免疫抑制劑轉向單株抗體，例如依庫Eculizumab、沙曲珠單抗和伊奈利珠單抗，這些抗體已被證實能有效降低復發率和致殘率。此外，臨床數據表明這些療法具有成本效益，這改善了保險報銷環境，儘管其成本較高，但保險公司現在對其給予了積極評價。這種正面的評價鼓勵醫院加強其治療基礎設施，進一步刺激了市場內的研發和投資，最終顯著提升了市場價值和治療可近性。

全球視神經脊髓炎頻譜障礙市場的成長要素

公眾和臨床醫生對視神經脊髓炎頻譜障礙 (NCD) 的認知不斷提高，顯著促進了症狀的早期發現，從而加快了患者轉診至專科醫生和啟動治療的速度。這種認知的提升最大限度地減少了診斷延誤，使患者能夠更早獲得現有療法和在研療法，最終改善治療效果，並增加對已通過核准和在研產品的需求。隨著越來越多的患者獲得適當的治療，全球醫療保健網路中各種醫療機構對診斷測試和標靶療法的應用日益廣泛，推動了市場的持續成長。這一趨勢正在支持頻譜市場的擴張。

全球視神經脊髓炎頻譜障礙市場的阻礙因素

新核准的單株抗體和生物製藥高成本，對醫療系統和患者都構成了重大障礙。保險公司通常會設定嚴格的報銷標準，限制了嚴重患者或對先前治療無效的患者獲得治療的機會。因此，許多符合條件的患者無法接受這些先進療法，或被迫依賴療效較差、過時的治療方法，阻礙了市場整體成長。此外，這些藥物的高昂費用也抑制了其在新興市場的廣泛應用，因為這些市場的預算有限，更傾向於選擇價格較低的替代療法。

視神經脊髓炎頻譜疾病（NMOSD）的全球市場趨勢

全球視神經脊髓炎頻譜障礙 (NMOSD) 市場正呈現出向精準診斷整合的顯著趨勢。高解析度成像技術和基於生物標記的檢測方法的日益普及，使得 NMOSD 與其他類似疾病的鑑別診斷能夠更早、更準確地進行。這種轉變促進了個人化治療方案的製定，並改變了患者轉診模式。伴隨診斷及相關服務需求的成長，提高了人們對治療效果的認知，並加速了藥物的推廣應用。隨著這些精準技術在醫療保健系統中日益重要，它們在 NMOSD 研究合作以及整個醫療保健生態系統的建構中發揮著至關重要的作用。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球視神經脊髓炎頻譜疾病市場規模：依治療方法分類。

• 伊尼利珠單抗（Uplizna）
• 沙曲珠單抗（恩斯普林）
• Eculizumab（Soliris）
• Rituximab

全球視神經脊髓炎頻譜疾病市場規模：依 AQP4 狀態分類

• AQP4抗體陽性
• AQP4抗體陰性

全球視神經脊髓炎頻譜疾病市場規模：依通路分類

• 醫院藥房
• 專科藥房

全球視神經脊髓炎頻譜疾病市場規模：依最終用戶分類。

• 神經科中心
• 醫院

全球視神經脊髓炎頻譜疾病市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Alexion（AstraZeneca）-Soliris/Uplizna
• Viela Bio（AstraZeneca）
• Chugai Pharmaceutical（Satralizumab）
• Genentech（Roche）
• Roche
• Mitsubishi Tanabe Pharma
• Horizon Therapeutics（Amgen）
• TG Therapeutics
• UCB SA
• Annexon Biosciences
• Imvax Inc.
• Shire（Takeda）
• MedDay Pharmaceuticals
• Novartis AG
• Biogen Inc.
• Clene Nanomedicine
• Inhibrx Inc.
• Opexa Therapeutics
• ProQR Therapeutics
• Nuvation Bio

結論與建議

Global Neuromyelitis Optica Spectrum Disorder Market size was valued at USD 1.52 Billion in 2024 and is poised to grow from USD 1.71 Billion in 2025 to USD 4.52 Billion by 2033, growing at a CAGR of 12.82% during the forecast period (2026-2033).

The neuromyelitis optica spectrum disorder (NMOSD) market is significantly influenced by advancements in diagnostics, particularly the aquaporin-4 IgG assay, which has refined the identification of this condition and increased reported prevalence. This development has catalyzed demand for targeted therapies, leading companies to transition from conventional immunosuppressants to monoclonal antibodies like eculizumab, satralizumab, and inebilizumab, which have demonstrated effectiveness in lowering relapse rates and disability. The reimbursement landscape has also improved as clinical data showcased the cost-effectiveness of these therapies, prompting insurers to classify them favorably despite their higher costs. Such acknowledgment has incentivized hospitals to enhance treatment infrastructure, further encouraging R&D and investment within the market, ultimately reflecting significant growth in market value and treatment accessibility.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Neuromyelitis Optica Spectrum Disorder market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Neuromyelitis Optica Spectrum Disorder Market Segments Analysis

Global neuromyelitis optica spectrum disorder market is segmented by treatment, aqp4 status, distribution, end-user and region. Based on treatment, the market is segmented into Inebilizumab (Uplizna), Satralizumab (Enspryng), Eculizumab (Soliris) and Rituximab. Based on aqp4 status, the market is segmented into AQP4 Antibody-Positive and AQP4 Antibody-Negative. Based on distribution, the market is segmented into Hospital Pharmacies and Specialty Pharmacies. Based on end-user, the market is segmented into Neurology Centers and Hospitals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Neuromyelitis Optica Spectrum Disorder Market

Rising public and clinician awareness of neuromyelitis optica spectrum disorder has significantly contributed to the early identification of symptoms, resulting in prompt referrals and initiation of treatments. This enhanced recognition minimizes diagnostic delays, allowing patients to access available and developing therapies earlier, thus improving treatment outcomes and increasing demand for both approved and pipeline products. As a greater number of patients receive suitable care, the market continues to grow, fueled by an increased uptake of diagnostic tests and targeted interventions across various healthcare environments within global health networks. This trend supports the expansion of the neuromyelitis optica spectrum disorder market.

Restraints in the Global Neuromyelitis Optica Spectrum Disorder Market

The high cost of newly approved monoclonal antibodies and biologic therapies serves as a considerable hurdle for healthcare systems and patients alike. Insurers often implement strict reimbursement standards, restricting access to individuals experiencing severe disease symptoms or those who have not responded to prior treatments. As a result, many patients who qualify for these advanced therapies remain untreated or are relegated to using older, less effective treatments, hindering overall market growth. Additionally, the financial sensitivity surrounding these medications deters broader adoption in emerging markets, where limited budgets necessitate a preference for more affordable alternatives.

Market Trends of the Global Neuromyelitis Optica Spectrum Disorder Market

The Global Neuromyelitis Optica Spectrum Disorder (NMOSD) market is experiencing a significant trend towards the integration of precision diagnostics. High-resolution imaging techniques and biomarker-driven assays are gaining traction, allowing for earlier and more accurate differentiation of NMOSD from similar disorders. This shift fosters customized therapeutic approaches, leading to a changing landscape in referral patterns towards specialized centers. The growing demand for companion diagnostics and associated services enhances the perception of treatment efficacy and accelerates drug adoption. As these precision technologies become fundamental within healthcare systems, they play a crucial role in shaping research collaborations and the overall care ecosystem for NMOSD.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Neuromyelitis Optica Spectrum Disorder Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Inebilizumab (Uplizna)
• Satralizumab (Enspryng)
• Eculizumab (Soliris)
• Rituximab

Global Neuromyelitis Optica Spectrum Disorder Market Size by AQP4 Status & CAGR (2026-2033)

• Market Overview
• AQP4 Antibody-Positive
• AQP4 Antibody-Negative

Global Neuromyelitis Optica Spectrum Disorder Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies

Global Neuromyelitis Optica Spectrum Disorder Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Neurology Centers
• Hospitals

Global Neuromyelitis Optica Spectrum Disorder Market Size & CAGR (2026-2033)

• North America (Treatment, AQP4 Status, Distribution, End-User)
  • US
  • Canada
• Europe (Treatment, AQP4 Status, Distribution, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, AQP4 Status, Distribution, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, AQP4 Status, Distribution, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, AQP4 Status, Distribution, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Alexion (AstraZeneca) - Soliris/Uplizna
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viela Bio (AstraZeneca)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chugai Pharmaceutical (Satralizumab)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech (Roche)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Tanabe Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Therapeutics (Amgen)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TG Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Annexon Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Imvax Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shire (Takeda)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MedDay Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clene Nanomedicine
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inhibrx Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Opexa Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ProQR Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nuvation Bio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations